Treatments and Targets to Achieve Disease Control in Chronic Spontaneous Urticaria: Current and Emerging Therapeutic Options - PubMed
a day ago
- #emerging treatments
- #chronic spontaneous urticaria
- #biologic therapy
- Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with unpredictable symptoms.
- First-line therapy includes second-generation H1-antihistamines, which can be up-dosed for better control.
- Omalizumab is effective for antihistamine-refractory cases, providing complete disease control in ~70% of patients.
- Newly approved add-on therapies like remibrutinib and dupilumab offer options for refractory patients.
- Cyclosporine is considered for severe cases but has potential serious adverse effects.
- Emerging treatments include KIT inhibitors, BTK inhibitors, TSLP inhibitors, JAK inhibitors, MRGPRX2 antagonists, and IL-2.
- The focus is shifting toward personalized and targeted management strategies for CSU.